Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ILK | Q13418 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405261 | 0.92 | APP (0.60) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL2243418 | 0.90 | MMP13 (0.63) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL1982194 | 0.85 | APP (0.64) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL2248504 | 0.84 | APP (0.52) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL12422162 | 0.84 | MMP13 (0.63) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL8535715 | 0.84 | APP (0.55) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL8532333 | 0.83 | APP (0.64) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL30844008 | 0.82 | EGFR (0.63) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL2248521 | 0.82 | EGFR (0.63) | MMP13APPMMP2MMP9MMP8 | |
| SCHEMBL11011564 | 0.81 | MMP13 (0.59) | MMP13APPMMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5874431-A | ANTITUMOR AGENTS; BREAST CANCER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-02-23 | — | — | US | disclosed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | MMP13 1063/4885APP 24/4885MMP2 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.